Other preclinical evidence has demonstrated potential synergy by disrupting menin and inhibiting BCL-2 or CDK6 with venetoclax or abemaciclib, respectively, in both AML cell lines as well as patient derived AML cell xenografts [63]. Here, BCL2 is linked to acute myeloid leukemia.